U.S. Metals and Mining Stock News

NYSE:MA
NYSE:MADiversified Financial

Mastercard Explores AI And Crypto Rails As Shares Trade Below Targets

Mastercard completed Europe’s first live AI agent initiated payment with Santander, showing how automated agents can move money within a regulated bank setting. The company also teamed up with MetaMask to launch a crypto self custody debit card across 49 U.S. states, connecting on chain funds to everyday spending. For investors watching NYSE:MA, these product moves come as the stock trades at $517.21, with a 4.3% gain over the past week and a 43.4% return over the past 3 years. Over 1 year...
NYSE:AMTM
NYSE:AMTMProfessional Services

A Look At Amentum Holdings (AMTM) Valuation After Hypersonics Contract And Nuclear Awards

Amentum Holdings (AMTM) has been attracting fresh attention after securing a contract to support the UK Ministry of Defence’s hypersonic weapons program, along with roughly US$1b in nuclear sector awards in FQ1 2026. See our latest analysis for Amentum Holdings. Amentum’s recent client wins in hypersonics and nuclear awards arrive after a mixed stretch for the stock, with a 16.5% 1 month share price decline but a 62% 1 year total shareholder return from today’s US$29.87 level. If this defence...
NasdaqCM:BLTE
NasdaqCM:BLTEPharmaceuticals

Assessing Belite Bio (BLTE) Valuation After Wider Fourth Quarter And Full Year Net Losses

Belite Bio (BLTE) shares are under the spotlight after the company reported a fourth quarter net loss of US$25.32 million and a full year net loss of US$77.61 million, both above prior-year levels. See our latest analysis for Belite Bio. Despite the wider losses, Belite Bio’s share price has shown strong momentum, with a 26.16% 90 day share price return and a very large 1 year total shareholder return that sits near 5x. This may point to shifting expectations around its pipeline rather than...
NYSE:SPGI
NYSE:SPGICapital Markets

A Look At S&P Global (SPGI) Valuation After Recent Share Price Volatility

Why S&P Global (SPGI) is on investors’ radar today S&P Global (SPGI) has drawn attention after recent trading left the stock with a mixed return profile, including negative moves over the past month and past 3 months despite longer term gains. See our latest analysis for S&P Global. At a share price of US$441.88, S&P Global has recently seen a 9.17% 7 day share price return after a weaker patch that included a 16.28% 30 day share price decline and a 15.86% 1 year total shareholder return...
NasdaqGS:LCID
NasdaqGS:LCIDAuto

A Look At Lucid Group (LCID) Valuation After Wider Losses Layoffs And Lower 2025 Production Guidance

Lucid Group (LCID) has come under fresh scrutiny after reporting a wider fourth quarter 2025 loss, workforce cuts of 12% in its U.S. salaried staff, and revised 2025 production figures. See our latest analysis for Lucid Group. The earnings miss, production revision and workforce cuts have coincided with a 1 year total shareholder return decline of 52.83% and a 3 year total shareholder return decline of 88.66%. The 90 day share price return decline of 22.36% suggests selling pressure has been...
NasdaqGS:VRNS
NasdaqGS:VRNSSoftware

Does Varonis (VRNS) SaaS Lawsuit Scrutiny Challenge The Credibility Of Its Growth Narrative?

In recent months, several law firms have filed securities class action lawsuits against Varonis Systems, alleging the company misled investors about its ability to convert customers to its SaaS platform and sustain ARR growth between February 4, 2025 and October 28, 2025. This legal pressure highlights a tension between the bullish long-term thesis on Varonis’ role in data-centric cybersecurity and fresh questions about the reliability of its past growth disclosures. We'll now examine how...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

A Look At GeneDx Holdings (WGS) Valuation After Breakthrough Device Win And Upgraded 2026 Outlook

GeneDx Holdings (WGS) has just put fresh numbers on the table, reporting its full year 2025 results along with reaffirmed 2026 revenue guidance and an FDA Breakthrough Device designation for its key genomic tests. See our latest analysis for GeneDx Holdings. Despite strong 2025 results, reaffirmed 2026 revenue guidance and the FDA Breakthrough Device designation, GeneDx’s recent share price momentum has been weak, with a 30 day share price return of 17.19% and a 90 day share price return of...
NasdaqGM:SEPN
NasdaqGM:SEPNPharmaceuticals

A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment

Septerna stock: recent moves and what they might mean for investors Septerna (SEPN) has attracted attention after a month return of about 24% and a past 3 months return above 10%, prompting investors to reassess how its clinical-stage biotech profile aligns with this recent share performance. See our latest analysis for Septerna. The recent 24.3% 1 month share price return, alongside a 10.9% 3 month share price return and a very large 1 year total shareholder return, suggests momentum has...
NYSE:USAC
NYSE:USACEnergy Services

A Look At USA Compression Partners (USAC) Valuation After Recent Unit Price Pullback

What USA Compression Partners stock’s recent performance suggests USA Compression Partners (USAC) has drawn investor interest after a period where the unit price showed a 1 day decline of about 1%, set against positive returns over the past month and the past 3 months. See our latest analysis for USA Compression Partners. That small 1 day share price pullback sits against a 30 day share price return of 5.65% and a 90 day gain of 10.97%, while the 5 year total shareholder return of 212.85%...
NYSE:HGTY
NYSE:HGTYInsurance

What Hagerty (HGTY)'s Strong 2025 Results but Loss-Making 2026 Markel Guidance Mean For Shareholders

Hagerty, Inc. recently reported its fourth-quarter and full-year 2025 results, with sales rising to US$221.42 million for the quarter and US$845.93 million for the year, and net income improving to US$6.92 million and US$41.46 million respectively. Alongside this stronger profitability, Hagerty issued 2026 guidance that includes lower reported revenue of about US$1.28–US$1.30 billion under a new Markel fronting arrangement and an expected net loss. Against this backdrop, we’ll now explore...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

A Look At BridgeBio Pharma (BBIO) Valuation After Phase 3 Wins And Attruby Commercial Momentum

BridgeBio Pharma (BBIO) is back in focus after reporting Q4 and full year 2025 results, showing sharply higher revenue alongside continued net losses as investors weigh the impact of recent clinical and commercial progress. See our latest analysis for BridgeBio Pharma. Despite the recent Q4 earnings and a series of positive Phase 3 readouts, BridgeBio Pharma’s short term share price returns have softened, with a 30 day share price return of 14.0% and year to date share price return of 15.0%...
NYSE:NPKI
NYSE:NPKITrade Distributors

Assessing NPK International (NPKI) Valuation After Strong Q4 Results And 2026 Revenue Outlook

Why the latest earnings and guidance matter for NPK International NPK International (NPKI) issued full year 2026 revenue guidance of US$305 million to US$325 million alongside fourth quarter 2025 results, giving investors fresh data on both recent performance and management expectations. The quarter included US$75.2 million in sales, net income of US$14.6 million, and diluted earnings per share of US$0.17. The company also reported completion of a previously announced US$20.29 million share...
NasdaqGS:FFIN
NasdaqGS:FFINBanks

A Look At First Financial Bankshares (FFIN) Valuation After Inflation And Credit Risk Jolt Bank Stocks

Recent inflation data came in hotter than expected, and renewed credit risk worries hit bank stocks broadly, including First Financial Bankshares (FFIN). Investors reassessed exposure to problem loans and economically sensitive lenders. See our latest analysis for First Financial Bankshares. The recent 7.5% one day share price decline and 7.2% 7 day share price return, on a last close of US$30.93, sits alongside a mildly positive year to date share price return of 3.03%. At the same time, the...
NasdaqGS:HTZ
NasdaqGS:HTZTransportation

Do Hertz’s External Disruptions And Fleet Refresh Plans Mark A Strategic Turning Point For HTZ?

In February 2026, Hertz Global Holdings, Inc. reported fourth-quarter 2025 results showing sales of US$2,028 million, with quarterly and full-year net losses narrowing year on year despite lower annual sales of US$8,504 million. The company attributed its wider-than-expected fourth-quarter loss to more than US$100 million of external disruptions, while outlining operational changes and fleet refresh plans aimed at improving earnings quality. Next, we’ll examine how these externally driven...
NYSE:TGT
NYSE:TGTConsumer Retailing

Target (TGT) Valuation Check As Earnings, Investor Meeting And Cereal Shift Refocus Market Expectations

Target (TGT) heads into a closely watched earnings report and investor meeting this week, just as it commits to selling only cereals without certified synthetic colors, a move that has triggered fresh scrutiny of the stock. See our latest analysis for Target. Those cereal changes land at a time when Target’s share price has climbed 25.78% over the past 90 days and 7.89% over the last 30 days, even as the 1 year total shareholder return is slightly negative and longer term total shareholder...
NasdaqGS:PGNY
NasdaqGS:PGNYHealthcare

Does Progyny's (PGNY) Buyback and ESOP Shelf Quietly Reframe Its Growth Story?

In late February 2026, Progyny completed a share repurchase of 6,530,363 shares for US$159.4 million and filed a US$93.26 million common stock shelf registration tied to an ESOP, shortly after reporting quarterly and full-year 2025 results that showed higher sales, net income, and earnings per share than a year earlier. Despite these milestones and record 2025 revenue and adjusted EBITDA, management’s cautious 2026 revenue guidance, adjusted for a large client transition, drew attention to...
NasdaqGS:LINE
NasdaqGS:LINEIndustrial REITs

Assessing Lineage (NasdaqGS:LINE) Valuation After Q4 Profit Swing And Narrowed Annual Net Loss

Lineage (LINE) is back in focus after reporting fourth quarter and full year 2025 results, which included a swing to a Q4 profit and a sharply smaller annual net loss, catching investors’ attention. See our latest analysis for Lineage. At a share price of US$40.52, Lineage has seen a 5.8% 7 day share price return, a 13.5% 30 day share price return, and a 14.4% year to date share price return. However, its 1 year total shareholder return of a 29.3% decline shows that recent momentum is...
NYSE:Q
NYSE:QSemiconductor

A Look At Qnity Electronics (Q) Valuation After Earnings Beat And New Buyback Plan

Why Qnity Electronics (Q) Is Back on Investors’ Radar Qnity Electronics (Q) has drawn fresh attention after reporting Q4 2025 results that topped analyst revenue and earnings expectations, rolling out a multi year productivity plan, and approving a US$500 million share repurchase program. See our latest analysis for Qnity Electronics. The strong Q4 surprise, fresh 2026 net sales guidance and new M&A ambitions have coincided with powerful momentum, with a 30 day share price return of 31.8% and...
NYSE:R
NYSE:RTransportation

Strong Quarter and Bullish 2026 Outlook Could Be A Game Changer For Ryder System (R)

Ryder System recently reported fourth-quarter 2025 results that exceeded expectations and paired them with an upbeat earnings outlook for 2026, highlighting resilient performance across its logistics and vehicle services operations. This strong update comes shortly after sizable insider share sales by senior executives, drawing attention to how leadership actions align with Ryder’s growth and capital allocation plans. With Ryder’s better-than-expected quarter and optimistic 2026 guidance now...
NasdaqGS:IRTC
NasdaqGS:IRTCMedical Equipment

A Look At iRhythm Holdings (IRTC) Valuation After Recent Share Price Weakness

iRhythm Holdings (IRTC) has drawn fresh attention after recent share price moves, with the stock showing a 4.6% decline over the past day and a 13.4% slide over the past month. See our latest analysis for iRhythm Holdings. The recent 1 day share price return of 4.6% decline adds to a 30 day share price return of 13.4% decline and a year to date share price return of 23.7% decline. At the same time, the 1 year total shareholder return of 22.6% shows a very different long term picture,...
NasdaqCM:SMPL
NasdaqCM:SMPLFood

A Look At Simply Good Foods (SMPL) Valuation After Founder’s Return And Insider Share Buying

Founder’s return and insider buying shift focus back to Simply Good Foods The Simply Good Foods (SMPL) story recently pivoted around founder Joe Scalzo’s return as CEO, his 2 million stock options, and a US$199,000 insider share purchase by the CFO, which has sharpened investor attention. See our latest analysis for Simply Good Foods. Despite the leadership shake up, Simply Good Foods’ recent share price return has been weak, with a 30 day share price decline of 9.11% and a 1 year total...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

How Leadership Turnover and Palazestrant Optimism At Olema Pharmaceuticals (OLMA) Has Changed Its Investment Story

In recent weeks, Olema Pharmaceuticals announced the departure of its COO and CFO, Shane Kovacs, who will remain as a consultant through August 1, 2026, while CEO Sean Bohen temporarily assumes principal financial officer responsibilities. At the same time, continued Buy ratings from Citi and new coverage from Stifel have put a spotlight on palazestrant’s commercial potential in the sizeable endocrine therapy market and growing hedge fund interest in the stock. With this context, we’ll...
NasdaqGS:NVCR
NasdaqGS:NVCRMedical Equipment

NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update

In late February 2026, NovoCure reported fourth-quarter 2025 revenue of US$174.35 million and a quarterly loss of US$24.5 million, alongside full-year 2025 revenue of US$655.35 million and a narrowed annual loss of US$136.23 million, while issuing 2026 net revenue guidance of US$675 million to US$705 million. Alongside these results, NovoCure secured U.S. FDA approval and began the commercial launch of Optune Pax for locally advanced pancreatic cancer, signaling a shift from a...
NYSE:STNG
NYSE:STNGOil and Gas

Why Scorpio Tankers (STNG) Is Up 10.1% After Pivot To Net Cash And Higher Dividend

In recent months, Scorpio Tankers reported strong fourth-quarter results, with net income rising to US$128.1 million and daily TCE rates increasing year over year, while shifting its balance sheet from US$3.10 billions in net debt in 2021 to roughly US$334 million in net cash by early 2026. The company complemented this financial improvement with a higher quarterly dividend of US$0.45 per share and continued investment in scrubber-fitted vessels, pointing to a focus on cash returns and...